{
  "symbol": "LLY",
  "year": 2022,
  "Period": "Y2022",
  "report_type": "K10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.1762,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.173
  },
  "top_positive": [
    {
      "sent": "78 Fair Value Measurements Using Description Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level\u00a01) Significant Other Observable Inputs (Level\u00a02) Significant Unobservable Inputs (Level\u00a03) Fair Value Long-term debt, including current portion December 31, 2021 $ ( 16,884.7 ) $ \u2014 $ ( 18,157.7 ) $ \u2014 $ ( 18,157.7 ) December 31, 2020 ( 16,595.3 ) \u2014 ( 19,038.9 ) \u2014 ( 19,038.9 ) 79 Fair Value Measurements Using Description Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level\u00a01) Significant Other Observable Inputs (Level\u00a02) Significant Unobservable Inputs (Level 3) Fair Value December 31, 2021 Risk-management instruments Interest rate contracts designated as fair value hedges: Other receivables $ 4.8 $ \u2014 $ 4.8 $ \u2014 $ 4.8 Other noncurrent assets 78.3 \u2014 78.3 \u2014 78.3 Other noncurrent liabilities ( 7.6 ) \u2014 ( 7.6 ) \u2014 ( 7.6 ) Interest rate contracts designated as cash flow hedges: Other noncurrent assets 49.2 \u2014 49.2 \u2014 49.2 Other noncurrent liabilities ( 31.7 ) \u2014 ( 31.7 ) \u2014 ( 31.7 ) Cross-currency interest rate contracts designated as net investment hedges: Other noncurrent assets 31.3 \u2014 31.3 \u2014 31.3 Other current liabilities ( 1.2 ) \u2014 ( 1.2 ) \u2014 ( 1.2 ) Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 33.2 \u2014 33.2 \u2014 33.2 Other noncurrent liabilities ( 1.3 ) \u2014 ( 1.3 ) \u2014 ( 1.3 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 9.9 \u2014 9.9 \u2014 9.9 Other current liabilities ( 35.3 ) \u2014 ( 35.3 ) \u2014 ( 35.3 ) Contingent consideration liabilities: Other noncurrent liabilities ( 70.5 ) \u2014 \u2014 ( 70.5 ) ( 70.5 ) December 31, 2020 Risk-management instruments Interest rate contracts designated as fair value hedges: Other noncurrent assets 158.9 \u2014 158.9 \u2014 158.9 Interest rate contracts designated as cash flow hedges: Other noncurrent assets 38.1 \u2014 38.1 \u2014 38.1 Other noncurrent liabilities ( 97.8 ) \u2014 ( 97.8 ) \u2014 ( 97.8 ) Cross-currency interest rate contracts designated as net investment hedges: Other current liabilities ( 92.6 ) \u2014 ( 92.6 ) \u2014 ( 92.6 ) Other noncurrent liabilities ( 97.2 ) \u2014 ( 97.2 ) \u2014 ( 97.2 ) Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 34.4 \u2014 34.4 \u2014 34.4 Other noncurrent liabilities ( 2.9 ) \u2014 ( 2.9 ) \u2014 ( 2.9 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 41.1 \u2014 41.1 \u2014 41.1 Other current liabilities ( 15.2 ) \u2014 ( 15.2 ) \u2014 ( 15.2 ) 80 Risk-management instruments above are disclosed on a gross basis.",
      "score": 0.9927
    },
    {
      "sent": "The fair values of our defined benefit pension plan and retiree health plan assets as of December\u00a031, 2021 by asset category were as follows: Fair Value Measurements Using Asset Class Total Quoted\u00a0Prices in Active Markets\u00a0for Identical Assets (Level 1) Significant Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Investments Valued at Net Asset Value (1) Defined Benefit Pension Plans Public equity securities: U.S.",
      "score": 0.9866
    },
    {
      "sent": "The strain on global transportation, logistics, and labor markets caused by the COVID-19 pandemic and an increase in overall demand in our industry for certain materials result\nin 2021, Top 50 Companies for Diversity by DiversityInc., America's Best Employers for Diversity by Forbes, America's Most JUST Companies and Forbes JUST 100 by Forbes and JUST Capital, Perfect Score on the Human Rights Campaign Foundation Corporate Equality Index, World's Most Ethical Companies by Ethisphere, Leading Disability Employer by the National Organization on Disability, Top Employers by Science Magazine, and 100 Best Companies, Top Companies for Executive Women, Best Companies for Dads, and Best Companies for Multicultural Women by Working Mother Magazine.",
      "score": 0.9851
    }
  ],
  "top_negative": [
    {
      "sent": "The failure, inadequacy, or breach of our IT systems or business processes, the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized access to, disclosure or use of, confidential information, or the unauthorized access to, disruption of, or interference with our products and services that rely on IT systems or business processes, could impair our ability to secure and maintain intellectual property rights; result in a product manufacturing interruption or failure, or in the interruption or failure of products or services that rely on IT systems or business processes; damage our operations, customer relationships, or reputation; result in unfavorable clinical trial results by virtue of incorrect or unreliable data; and/or cause us to lose trade secrets or other competitive advantages.",
      "score": -0.9753
    },
    {
      "sent": "The failure, inadequacy, or breach of our IT systems or business processes, the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized access to, disclosure or use of, confidential information, or the unauthorized access to, disruption of, or interference with our products and services that rely on IT systems or business processes, could impair our ability to secure and maintain intellectual property rights; result in a product manufacturing interruption or failure, or in the interruption or failure of products or services that rely on IT systems or business processes; damage our operations, customer relationships, or reputation; result in unfavorable clinical trial results by virtue of incorrect or unreliable data; and/or cause us to lose trade secrets or other competitive advantages.",
      "score": -0.9753
    },
    {
      "sent": "The failure, inadequacy, or breach of our IT systems or business processes, the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized access to, disclosure or use of, confidential information, or the unauthorized access to, disruption of, or interference with our products and services that rely on IT systems or business processes, could impair our ability to secure and maintain intellectual property rights; result in a product manufacturing interruption or failure, or in the interruption or failure of products or services that rely on IT systems or business processes; damage our operations, customer relationships, or reputation; result in unfavorable clinical trial results by virtue of incorrect or unreliable data; and/or cause us to lose trade secrets or other competitive advantages.",
      "score": -0.9753
    }
  ],
  "forward_snippets": [
    "The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated: \u2022 the impact of the evolving COVID-19 pandemic or any future pandemic, epidemic, or similar public health threat and the global response thereto; \u2022 uncertainties related to our efforts to develop, manufacture, and distribute potential treatments for COVID-19; \u2022 the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; \u2022 the impact and outcome of acquisitions and business development transactions and related integration costs; \u2022 the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products; \u2022 our ability to protect and enforce patents and other intellectual property; \u2022 changes in patent law or regulations related to data package exclusivity; \u2022 competitive developments affecting current products and our pipeline; \u2022 market uptake of recently launched products; \u2022 information technology system inadequacies, breaches, or operating failures; \u2022 unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data; \u2022 unexpected safety or efficacy concerns associated with our products; \u2022 litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured; \u2022 issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of demand, labor shortages, third-party performance, or regulatory actions relating to our facilities; \u2022 reliance on third-party relationships and outsourcing arrangements; \u2022 regulatory changes or other developments; \u2022 regulatory actions regarding currently marketed products; \u2022 continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals; \u2022 devaluations in foreign currency exchange rates, changes in interest rates, and inflation; \u2022 changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; \u2022 asset impairments and restructuring charges; 3 \u2022 the impact of global macroeconomic conditions, trade disruptions, global disputes, unrest, war, or other costs, uncertainties and risks related to engaging in business in foreign jurisdictions; \u2022 changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); and \u2022 regulatory compliance problems or government investigations.",
    "\u2022 Trajenta \u00ae , in collaboration with Boehringer Ingelheim, \nthreat and the global response thereto; \u2022 uncertainties related to our efforts to develop, manufacture, and distribute potential treatments for COVID-19; \u2022 the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; \u2022 the impact and outcome of acquisitions and business development transactions and related integration costs; \u2022 the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products; \u2022 our ability to protect and enforce patents and other intellectual property; \u2022 changes in patent law or regulations related to data package exclusivity; \u2022 competitive developments affecting current products and our pipeline; \u2022 market uptake of recently launched products; \u2022 information technology system inadequacies, breaches, or operating failures; \u2022 unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data; \u2022 unexpected safety or efficacy concerns associated with our products; \u2022 litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured; \u2022 issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of demand, labor shortages, third-party performance, or regulatory actions relating to our facilities; \u2022 reliance on third-party relationships and outsourcing arrangements; \u2022 regulatory changes or other developments; \u2022 regulatory actions regarding currently marketed products; \u2022 continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals; \u2022 devaluations in foreign currency exchange rates, changes in interest rates, and inflation; \u2022 changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; \u2022 asset impairments and restructuring charges; 3 \u2022 the impact of global macroeconomic conditions, trade disruptions, global disputes, unrest, war, or other costs, uncertainties and risks related to engaging in business in foreign jurisdictions; \u2022 changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); and \u2022 regulatory compliance problems or government investigations.",
    "We believe our long-term competitive success depends on discovering and developing (either alone or in collaboration with others) or acquiring innovative, cost-effective products that provide improved outcomes for patients and deliver value to payers, and continuously improving the productivity of our operations in a highly competitive environment.",
    "Biosimilars A number of our products and potential new medicines in our clinical-stage pipeline are biologics.",
    "However, in March 2020, the FDA began regulating all of our insulin products as \"biologics\" rather than \"drugs.\" Based on FDA draft guidance, this change may lessen the amount of data required for competitor biosimilar products to enter the market, some of which could be designated as interchangeable and therefore substituted for our insulin products at U.S."
  ]
}